The Rheumatologist
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
  • Technology
    • Electronic Health Records
    • Apps
    • Information Technology
  • Resources
    • Issue Archives
    • Events
    • Multimedia
      • Audio
      • Video
    • From the College
    • American College of Rheumatology
    • Rheumatology Research Foundation
    • Arthritis & Rheumatology
    • Arthritis Care & Research
    • Treatment Guidelines
    • Research Reviews
    • Annual Meeting
      • Abstracts
      • Meeting Reports
    • Rheumatology Image Bank
    • ACR ExamRheum
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Samsung Bioepis Receives Final European Approval for Its Remicade Copy

Samsung Bioepis Receives Final European Approval for Its Remicade Copy

June 1, 2016 • By Reuters Staff

  • Tweet
  • Email
Print-Friendly Version / Save PDF

SEOUL (Reuters)—South Korea’s Samsung Bioepis said on Monday its biosimilar of Johnson & Johnson’s blockbuster rheumatoid arthritis drug Remicade (infliximab) has received final approval from European regulators, paving the way for its second product launch in Europe.

You Might Also Like
  • AbbVie, Samsung Bioepis in Deal; Humira Biosimilar U.S. Release in 2023
  • Pfizer’s Second Biosimilar of J&J’s Remicade Wins U.S. FDA Approval
  • FDA Approves Biosimilar to J&J’s Remicade for Multiple Diseases

Samsung Bioepis, an unlisted arm of South Korea’s top conglomerate Samsung Group, also said last week the biosimilar had been submitted for review in the U.S.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

A relative latecomer to the industry, Samsung Bioepis has found early success by beating rivals to market on some of the world’s top-selling drugs. It became the first company to launch a biosimilar version of Amgen’s Enbrel (etanercept), another rheumatoid arthritis drug, in Europe.

Samsung Biologics, Bioepis’ parent company, is planning an initial public offering in South Korea by the end of the year that analysts say could raise up to 3 trillion won ($2.5 billion).

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Samsung Bioepis says minority shareholder and partner Biogen will be responsible for the commercialisation and distribution of its Remicade copy, called Flixabi in Europe.

Biosimilars, lower-cost copies of complex biotech drugs, are still relatively new but interest is growing quickly as firms, such as Bioepis, launch cheaper versions of blockbuster drugs.

The Samsung Group hopes the biosimilars business will develop into a new growth driver as global demand for smartphones plateaus, weighing on the outlook for its flagship firm Samsung Electronics.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Filed Under: Biologics & Biosimilars, Drug Updates, Pharma Co. News Tagged With: Biosimilars, infliximab, infliximab-dyyb, International, Remicade

You Might Also Like:
  • AbbVie, Samsung Bioepis in Deal; Humira Biosimilar U.S. Release in 2023
  • Pfizer’s Second Biosimilar of J&J’s Remicade Wins U.S. FDA Approval
  • FDA Approves Biosimilar to J&J’s Remicade for Multiple Diseases
  • U.S. Appeals Court Invalidates J&J Patent on Remicade

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

ACR/ARP Annual Meeting

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Annual Meeting site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2019 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.